Artrya (ASX:AYA) won a 36-month commercial contract with Lumus Imaging for the use of the Salix Coronary Anatomy platform, according to a Tuesday filing with the Australian bourse.
Salix is designed to detect critical markers, including high-risk plaque, from CT coronary angiogram scans generated by a photon-counting CT scanner, per the filing.
The contract is expected to bring in revenue through a software-as-a-service subscription model, the filing stated.
Artrya's shares were up 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.